The present invention relates to a process for preparing N-(1-alkenyl)carboxamides of the formula I, which comprises reacting a carboxamide of the formula II with an alkyne of the formula III in the presence of a catalyst selected from among carbonyl complexes, halides and oxides of rhenium, manganese, tungsten, molybdenum, chromium and iron.
作者:Philip Lamers、Daniel L. Priebbenow、Carsten Bolm
DOI:10.1002/ejoc.201500855
日期:2015.9
As a result of our recent investigations into the N-functionalization of sulfoximines, an iron-catalyzed dealkylative acylation of N-alkylsulfoximines has been developed. This process involves a Polonovski-type dealkylation of an N-alkylated sulfoximine to afford a reactive intermediate that is trapped in the presence of a suitable aldehyde or anhydride to afford N-acyl- and N-aroylsulfoximine derivatives
Lawesson's reagent for direct thionation of hydroxamic acids: Substituent effects on LR reactivity
作者:Witold Przychodzeń
DOI:10.1002/hc.20259
日期:——
To explore the generality and scope of direct thionation of hydroxamicacids (HAs), the reaction of various structurally diverse HAs with Lawesson's reagent was investigated. The yield of thiohydroxamic acid (THAs) is poor when HAs possess bulky acyl and/or N-substituents, acidic α-hydrogen atoms, or an N-phenyl ring. THAs yields were correlated with Brown sigma parameter. The relative rates of two
[EN] AZOLE AMIDES AND AMINES AS ALPHA V INTEGRIN INHIBITORS<br/>[FR] AMIDES D'AZOLE ET AMINES EN TANT QU'INHIBITEURS D'INTÉGRINE ALPHA V
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2018089358A1
公开(公告)日:2018-05-17
The present invention provides compounds of Formula (I): (Formula (I)), or stereoisomers, tautomers, or pharmaceutically acceptable salts or solvates thereof, wherein all the variables are as defined herein. These compounds are inhibitors to αv-containing integrins. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating a disease, disorder, or condition associated with dysregulation of αv-containing integrins, such as pathological fibrosis, transplant rejection, cancer, osteoporosis, and inflammatory disorders, by using the compounds and pharmaceutical compositions.
Ionic Liquids for Separation of Olefin-Paraffin Mixtures
申请人:Dai Sheng
公开号:US20110015461A1
公开(公告)日:2011-01-20
The invention is directed to an ionic liquid comprising (i) a cationic portion containing a complex of a silver (I) ion and one or more neutral ligands selected from organoamides, organoamines, olefins, and organonitriles, and (ii) an anionic portion having the chemical formula
wherein m and n are independently 0 or an integer of 1 or above, and p is 0 or 1, provided that when p is 0, the group —N—SO
2
—(CF
2
)
n
CF
3
subtended by p is replaced with an oxide atom connected to the shown sulfur atom. The invention is also directed to a method for separating an olefin from an olefin-paraffin mixture by passing the mixture through a layer of the ionic liquid described above.